2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|September 2, 2003
- Pharmaceutical Technology-09-02-2003
- Volume 27
- Issue 9
The Fabrication And Evaluation of the Formulation Variables of a Controlled-Porosity Osmotic Drug Delivery System with Diltiazem Hydrochloride
Author(s)Kilambi Pundarikakshudu, PhD
The study presented in this article used a controlled-porosity osmotic pump, which was prepared in the form of a bilayered tablet containing a drug compartment and an osmogen layer for the delayed release of diltiazem HCI.
Advertisement
Articles in this issue
about 23 years ago
September 2003about 23 years ago
In the Spotlight September 2003about 23 years ago
Counterfeiting, Compliance, and Controlsabout 23 years ago
September 2003about 23 years ago
Disposable Filtration Lightens Cleaning and Validation Loadabout 23 years ago
CROs Hoping for Research Burst in Second Half of 2003Advertisement
Related to this article
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
3
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
4
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
5